Payment overview · 2025
General Payments
$1,943.79
127 reported records · 24 companies
Healthcare provider profile · identity verified
Yoram Moyal, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MAYFIELD VILLAGE, OH · NPI 1194730580
Verified facts
What the public records show
CMS Open Payments records show Yoram Moyal, MD received $1,943.79 in general payments during 2025 across 127 reported records.
ABBVIE INC. accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Viberzi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $377.12 | 19.4% | 28 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $271.49 | 14.0% | 16 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $163.75 | 8.4% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $158.36 | 8.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $139.86 | 7.2% | 12 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $88.68 | 4.6% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $79.72 | 4.1% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $74.88 | 3.9% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $69.28 | 3.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $65.98 | 3.4% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $61.77 | 3.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $51.31 | 2.6% | 3 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $46.01 | 2.4% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.51 | 2.3% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $43.87 | 2.3% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.62 | 1.9% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $35.29 | 1.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.30 | 1.3% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $20.85 | 1.1% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.66 | 1.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.64 | 1.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.85 | 0.9% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $15.36 | 0.8% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.63 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,943.79 | 127 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $236.79 | 14 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $212.37 | 10 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $155.72 | 11 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $155.72 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.15 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $124.39 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $120.21 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $120.21 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $113.10 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $100.20 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $96.43 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $96.43 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $92.71 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $91.18 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $89.06 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $79.72 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $74.88 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $69.28 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $61.77 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $51.31 | 3 | 2025 |
Source payment records
|
|||||
| QSYMIA Normalized: qsymia |
Drug | VIVUS LLC | $46.01 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $45.51 | 13 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $43.87 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $43.54 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $43.43 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $37.62 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.00 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $28.49 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $25.30 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| VARIVAX Normalized: varivax |
Biological | Merck Sharp & Dohme LLC | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $11.76 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $8.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 53 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 105 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
105 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 475 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 430 | 123 |
| Losartan Potassium | Losartan Potassium | 300 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 284 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 279 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 225 | 59 |
| Omeprazole | Omeprazole | 181 | 52 |
| Gabapentin | Gabapentin | 180 | 45 |
| Metformin Hcl | Metformin Hcl | 176 | 41 |
| Azithromycin | Azithromycin | 159 | 108 |
| Carvedilol | Carvedilol | 153 | 48 |
| Allopurinol | Allopurinol | 150 | 37 |
| Methylprednisolone | Methylprednisolone | 149 | 111 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 145 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 144 | 46 |
| Lisinopril | Lisinopril | 139 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 123 | 35 |
| Montelukast Sodium | Montelukast Sodium | 122 | 34 |
| Glimepiride | Glimepiride | 117 | 26 |
| Mounjaro | Tirzepatide | 105 | 16 |
| Simvastatin | Simvastatin | 105 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 30 |
| Alprazolam | Alprazolam | 98 | 17 |
| Furosemide | Furosemide | 97 | 34 |
| Mirtazapine | Mirtazapine | 95 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 28 |
| Potassium Chloride | Potassium Chloride | 91 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 23 |
| Sertraline Hcl | Sertraline Hcl | 81 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 73 | 40 |
| Trazodone Hcl | Trazodone Hcl | 73 | 22 |
| Buspirone Hcl | Buspirone Hcl | 72 | 22 |
| Dexamethasone | Dexamethasone | 72 | 57 |
| Ezetimibe | Ezetimibe | 72 | 23 |
| Prednisone | Prednisone | 71 | 47 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 19 |
| Clonazepam | Clonazepam | 67 | suppressed |
| Finasteride | Finasteride | 64 | 19 |
| Ozempic | Semaglutide | 64 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | suppressed |
| Eliquis | Apixaban | 53 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 18 |
| Meloxicam | Meloxicam | 47 | 18 |
| Memantine Hcl | Memantine Hcl | 47 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 47 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 45 |
| Repatha Sureclick | Evolocumab | 46 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | 12 |
| Jardiance | Empagliflozin | 41 | suppressed |
| Atenolol | Atenolol | 39 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 38 | 30 |
| Spironolactone | Spironolactone | 38 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | 11 |
| Azelastine Hcl | Azelastine Hcl | 32 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 14 |
| Torsemide | Torsemide | 31 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 25 | 11 |
| Famotidine | Famotidine | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 20 |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 18 |
| Cephalexin | Cephalexin | 22 | 18 |
| Folic Acid | Folic Acid | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dapsone | Dapsone | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,943.79 · 127 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AMYVID, ATRICLIP LAA EXCLUSION SYSTEM, Auvelity, BREZTRI, CAPVAXIVE, COMIRNATY, CREON, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, KISUNLA, Kerendia, Korlym, LEQVIO, LINZESS, M-M-R II, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QSYMIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, SYNTHROID, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, ULTOMIRIS, VARIVAX, VOQUEZNA, VRAYLAR, Veozah, WaveWriter Alpha Prime 16, ZAVZPRET, ZENPEP, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error